HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)

South Korea · Delayed Price · Currency is KRW

2,755.00

+260.00 (10.42%)

Nov 2, 2026, 3:30 PM KST

Market Cap	242.82B -13.0%
Revenue (ttm)	64.45B +5.2%
Net Income	-18.02B
EPS	-204.99
Shares Out	88.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	612,301
Open	2,600.00
Previous Close	2,495.00
Day's Range	2,480.00 - 2,785.00
52-Week Range	1,342.00 - 4,160.00
Beta	-0.54
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About HLB Therapeutics

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 49

Stock Exchange KOSDAQ

Ticker Symbol 115450

Full Company Profile

Financial Performance

In 2025, HLB Therapeutics's revenue was 69.56 billion, an increase of 26.63% compared to the previous year's 54.93 billion. Losses were -9.23 billion, -59.52% less than in 2024.

Financial Statements